Insilico’s AI-Driven CKD Anemia Drug Enters Phase I Trials in China
Event summary
- ISM4808, an AI-discovered PHD inhibitor for CKD-related anemia, completed first human dosing in Phase I trials.
- TaiGen initiated the trial within three months of licensing the drug from Insilico in December 2025.
- The deal includes upfront payments, milestone-based royalties, and exclusive rights for TaiGen in Greater China.
- Phase I is a randomized, double-blind study evaluating safety, tolerability, and pharmacokinetics in healthy adults.
The big picture
Insilico’s collaboration with TaiGen highlights the growing role of AI in accelerating drug discovery, particularly for underserved conditions like CKD-related anemia. The deal underscores the strategic value of out-licensing in expanding geographic reach while mitigating development risk. With tens of millions in potential royalties at stake, success here could validate Insilico’s AI-driven pipeline strategy.
What we're watching
- Execution Speed
- Whether TaiGen can sustain rapid clinical progress after this initial milestone.
- Market Differentiation
- How ISM4808’s oral administration and safety profile will compete against existing ESAs.
- AI Validation
- The pace at which Insilico’s Chemistry42 platform delivers additional clinical-stage candidates.
Related topics